Clinical trials: SARS (Severe Acute Respiratory Syndrome)
SARS-CoV-2 Infection
Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient
Determine the efficacy and safety of COVID19-0001-USR in the treatment of SARS-COV-2 infection in mild to moderate manifestations administered via nebulization/inhalation.
- Trial name
- COVID-19 (NCT04595136)
- Testing
- Drug COVID19-0001-USR, normal saline
- Where
- Colombia
- Volunteers
- 60 people
- Sponsor
- United Medical Specialties
Covid19, SARS-CoV Infection
Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified.
- Conditions
- Covid19, SARS-CoV Infection, Transplantation Infection
- Trial name
- COVITRA (NCT04579471)
- Testing
- SARS-CoV-2 IgG
- Where
- Belgium
- Volunteers
- 2,000 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Acute Respiratory Distress Syndrome, ARDS
Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure
This is a quality improvement study with the purpose of observing and measuring the effects of implementation of a proven standardized lung protective ventilation protocol in the new electronic medical record system iCentra…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS, Respiratory Distress Syndrome, Acute, Respiratory Insufficiency
- Trial name
- IMPROVENT (NCT03225807)
- Where
- United States
- Volunteers
- 8,692 people
- Sponsor
- Intermountain Health Care, Inc.
COVID-19 Pandemic
Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.
- Trial name
- NCT05236309
- Testing
- Jing-Guan-Fang(JGF) : Chinese herbal decoction
- Where
- Taiwan
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Taipei City Hospital
Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2
Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19
The COVID-19 pandemic has had a dramatic effect in public health worldwide. In Brazil, there have been more than 2 million confirmed cases and over 75,000 deaths since February 26, 2020.
- Trial name
- RUXO-COVID (NCT04477993)
- Testing
- Janus Kinase Inhibitor (ruxolitinib)
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Vanderson Geraldo Rocha
Covid19, SARS-CoV Infection
Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine
Multicenter, randomized, blind, placebo-controlled clinical study of III phases on the assessment of preventive efficiency, safety and immunogenicity QazCovid-in®-vaccine against COVID-19 in healthy adult volunteers
- Conditions
- Covid19, SARS-CoV Infection, Vaccine Adverse Reaction
- Trial name
- NCT04691908
- Testing
- QazCovid-in®-vaccine against COVID-19
- Where
- Kazakhstan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
Covid19, SARS-CoV Infection
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
This is a prospective, placebo controlled, individually randomized controlled phase III trial in Primary Care, assessing the efficacy of antivirals, i.e. camostat and molnupiravir, in accelerating recovery in Covid-19 patients.
- Trial name
- DAWN (NCT04730206)
- Testing
- Camostat, Molnupiravir
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- KU Leuven
SARS-CoV Infection, COVID 19
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients
The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and…
- Conditions
- SARS-CoV Infection, COVID 19, Acute Respiratory Distress Syndrome ARDS
- Trial name
- NCT04321616
- Testing
- Hydroxychloroquine, Remdesivir, (Standard of Care) SoC
- Where
- Norway
- Volunteers
- 700 people
- Sponsor
- Oslo University Hospital
Severe Acute Respiratory Syndrome Coronavirus 2
A Clinical Trial of COVAC-2 in Healthy Adults
VIDO has developed a vaccine called COVAC-2. The study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host…
- Trial name
- NCT04702178
- Testing
- COVAC-2
- Where
- 2 sites in Canada
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Severe Acute Respiratory Syndrome
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related…
- Trial name
- OSCAR (NCT04376684)
- Testing
- Otilimab, Standard of care
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 1,156 people
- Sponsor
- GlaxoSmithKline
Covid19, SARS-CoV Infection
COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
- Trial name
- COVID-FIS (NCT04537299)
- Testing
- Fisetin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
COVID, SARSCoV2 Convalescent Plasma
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)
Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel coronavirus disease (COVID-19…
- Trial name
- NCT04374370
- Testing
- SARSCoV2 Convalescent Plasma
- Where
- United States
- Sponsor
- AdventHealth
COVID-19, Comorbidities and Coexisting Conditions
Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study
This is a two-phase multicenter study that will be conducted in collaboration with five university hospitals, in order to offer telehealth services at home in patients with COVID-19, after hospital discharge.
- Trial name
- ATHLOS (NCT04368845)
- Testing
- Telerehabilitation
- Where
- Greece
- Volunteers
- 82 people
- Sponsor
- University of Thessaly
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05614245
- Testing
- VBI-2901e
- Where
- 4 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19 Related Health and Infection Control Practices Among Dentists
As dentists begin reopening their practices during a global pandemic, the risk of COVID-19 infection that dentists face in providing dental care remains unknown.
- Trial name
- NCT04423770
- Testing
- No intervention
- Where
- United States
- Volunteers
- 2,196 people, healthy volunteers welcome
- Sponsor
- American Dental Association
SARS-CoV 2, COVID
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or…
- Conditions
- SARS-CoV 2, COVID, ARDS, ALI
- Trial name
- AVICOVID-3 (NCT05137795)
- Testing
- ZYESAMI™ (aviptadil acetate)
- Sponsor
- APR Applied Pharma Research s.a.
Hypoxemia, Severe Acute Respiratory Syndrome
Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial
Multicenter, parallel-group, randomized clinical trial comparing the administration of systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days vs no corticosteroid administration among adults…
- Trial name
- STAR (NCT07199192)
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV Infection, Covid19
Cross Sectional CFAR HIV/COVID-19 Study
The main purpose of this research study is to learn the rate of SARS COV-2 on HIV infected children, adolescents, and youth receiving their primary HIV care at the University of Miami Miller School of Medicine.
- Trial name
- NCT04514016
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Miami
Bioavailability
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants.
- Trial name
- NCT05263921
- Testing
- PF-07321332/ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer